Ziresovir

Ziresovir

Ziresovir is an experimental antiviral drug currently under investigation for its potential use in the treatment of respiratory syncytial virus (RSV) infections. It is a small molecule inhibitor of the RSV fusion (F) protein, which is essential for the virus's ability to enter host cells and initiate an infection.

Mechanism of Action

Ziresovir works by inhibiting the fusion of the RSV virus with the host cell membrane, a critical step in the viral life cycle. The drug binds to the RSV F protein, preventing it from undergoing the conformational changes necessary for fusion with the host cell. This effectively blocks the virus from entering the cell and initiating an infection.

Clinical Trials

Ziresovir has undergone Phase I and II clinical trials to evaluate its safety, tolerability, and efficacy in treating RSV infections. The results of these trials have shown promise, with Ziresovir demonstrating a good safety profile and potential efficacy against RSV.

Potential Applications

If approved, Ziresovir could be used to treat RSV infections in high-risk populations, such as infants, the elderly, and immunocompromised individuals. It could also potentially be used prophylactically to prevent RSV infections in these high-risk groups.

See Also

• Antiviral drug
• Respiratory syncytial virus
• Clinical trial

References

This antiviral drug related article is a stub. You can help WikiMD by expanding it.